Trial Profile
Prospective study investigating safety and efficacy of Sitagliptin with continuous subcutaneous insulin infusion (CSII) therapy against CSII monotherapy in patients newly diagnosed with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Nov 2015
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 28 Nov 2015 New trial record